Editorial
|
|
|
|
|
Trading the known for the unknown
|
|
|
|
New Products
|
|
|
|
|
An option for patients informed of the uncertainties
|
|
|
|
|
|
|
|
|
|
|
|
Philadelphia chromosome-positive leukaemia: uncertain efficacy, proven thromboembolic risk
|
|
|
|
|
|
|
|
|
|
Warfarin remains the standard drug
|
|
|
|
|
|
|
|
|
|
Better short-term visual acuity but serious adverse effects
|
|
|
|
|
|
|
|
|
|
Too many adverse effects and uncertainties
|
|
|
|
|
|
|
|
|
|
No better than allopurinol
|
|
|
|
Adverse Effects
|
|
|
|
|
Epidemiological studies are needed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beware of behavioural changes
|
|
|
|
Reviews
|
|
|
|
|
Nicotine replacement, e-cigarettes
|
|
|
|
|
|
|
|
|
|
Pros and cons of corticosteroids
|
|
|
|
Outlook
|
|
|
|
|
Making drug names safer by contributing to INN selection
|
|
|
|
|
|
|
|
|
|
The finances of Association Mieux Prescrire: 2014 Prescrire annual report
|
|
|
|
|
|